Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on August 11, 2005, reporting events that occurred on August 8, 2005. The company is a Delaware corporation focused on developing drug candidates.
Key Financial Metrics and Capital Structure
The filing details a significant capital raise through two simultaneous private placements conducted offshore under Regulation S:
- Convertible Notes: Issued $1.3 million in aggregate principal amount of convertible notes.
- Common Stock: Sold 4,175,000 shares of common stock at $2.00 per share.
- Total Gross Proceeds: $9.65 million ($1.3 million from notes + $8.35 million from stock).
- Net Proceeds: Approximately $8.31 million received from the stock sale after expenses; net proceeds from notes are not explicitly stated after expenses.
- Use of Proceeds: Funding clinical trials for drug candidates and general corporate purposes.
Material Changes and Transaction Terms
The primary material change is the increase in debt and equity capital. Key terms include:
- Conversion Terms: Notes are convertible into common stock at $2.00 per share starting September 19, 2005, until the maturity date of August 8, 2008. Unconverted notes automatically convert at maturity.
- Interest: Notes bear no interest unless overdue or in default, at which point interest accrues at 5% per annum.
- Adjustments: The conversion price is subject to adjustment if the company issues additional capital stock at a price below the current market price.
Outlook, Risks, and Contingencies
Management intends to utilize the raised capital to advance clinical trials. The filing notes that the securities issued (both notes and stock) are unregistered under the Securities Act and cannot be resold in the United States without registration or an applicable exemption. The filing does not provide specific financial guidance, revenue projections, or liquidity ratios beyond the immediate cash infusion.
Investor Verification Checklist
- Verify the total dilution impact of the 4,175,000 new shares plus potential conversion of the $1.3 million in notes.
- Confirm the specific clinical trial milestones expected to be funded by the $8.31 million in net proceeds.
- Review the full text of the Convertible Note (Exhibit 4.1) for specific default triggers and anti-dilution mechanics.
- Check subsequent filings for the registration status of these securities to determine when they may be tradable in the U.S.